Zhexue Wang

Mr. Zhexue Wang

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2024 in Clinical Surgical Oncology
Verified
Journal Article
Open access
ZWZhexue Wang
Zhexue Wang
JBJunge Bai
Junge Bai
DJDedi Jiang
Dedi Jiang
YLYuegang Li
Yuegang Li
XHXiyue Hu
Xiyue Hu
XWXishan Wang
Xishan Wang

9 November 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
LZLiming Zhao
Liming Zhao
ZWZhexue Wang
Zhexue Wang
PCPu Cheng
Pu Cheng
GSGuoli Sheng
Guoli Sheng
MHMingyu Han
Mingyu Han
ZZZhaoxu Zheng
Zhaoxu Zheng
Background: Colorectal cancer (CRC) mortality is predominantly driven by liver metastasis and poor responsiveness to chemotherapy. The histone methyltransferase SMYD3 has been implicated in oncogenic transcriptional programs; however, its downstream effectors and microenvironmental roles in CRC remain unclear. Methods: We investigated whether SMYD3 regulates the transcription and function of the membrane receptor CDCP1, which mediates Src/PKCδ signaling and promotes invasion and stromal remodeling. A combination of molecular assays, including ChIP-qPCR, Western blotting, and co-culture experiments, was employed to examine the SMYD3–CDCP1 axis and its impact on epithelial–mesenchymal transition (EMT), cancer-associated fibroblast (CAF) activation, and oxaliplatin (OXA) sensitivity. Results: SMYD3 directly bound to the CDCP1 promoter and catalyzed H3K4me3 enrichment, thereby enhancing CDCP1 transcription. Upregulated CDCP1 activated Src/PKCδ signaling, facilitating EMT and CAF activation within the tumor microenvironment. Genetic suppression of SMYD3 reduced metastatic potential and improved oxaliplatin response in vivo, while genetic or pharmacologic perturbation attenuated tumor–stroma crosstalk and enhanced oxaliplatin sensitivity in vitro. Conclusions: The SMYD3–CDCP1 axis drives CRC progression by epigenetically promoting CDCP1 transcription and remodeling the tumor microenvironment. Targeting this pathway may provide a promising therapeutic strategy to restrain metastasis and enhance chemotherapy efficacy in CRC.

3 September 2026 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
ZLZheng Liu
Zheng Liu
ZWZhexue Wang
Zhexue Wang
Liu YangLiu Yang
Liu Yang
ZMZhiqiang Ma
Zhiqiang Ma
SWSheng Wang
Sheng Wang
XWXishan Wang
Xishan Wang

22 February 2024 in Clinical Surgical Oncology
Verified
Journal Article
Open access
JSJinxin Shi
Jinxin Shi
JCJian Cui
Jian Cui
WXWenrui Xu
Wenrui Xu
ZWZhexue Wang
Zhexue Wang
JBJunge Bai
Junge Bai
QAQi An
Qi An

20 January 2026 in Clinical Surgical Oncology
Verified
Journal Article
Open access
ZLZheng Liu
Zheng Liu
ZWZhexue Wang
Zhexue Wang
Liu YangLiu Yang
Liu Yang
ZMZhiqiang Ma
Zhiqiang Ma
SWSheng Wang
Sheng Wang
XWXishan Wang
Xishan Wang